Clinical trials: Factor V Leiden
Antiphospholipid Syndrome, Factor V Leiden Thrombophilia
Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome
The primary objective of this study was to evaluate and compare the prevalence of the following psychiatric pathologies (based on the MINI5.0.0 questionnaire) among 3 groups of women (Leiden versus aP1Ab-positive versus…
- Trial name
- NOHA-PSY (NCT02833194)
- Where
- France
- Volunteers
- 1,592 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Leiden Factor V Deficiency,Preeclampsia, Doppler Examination
Prediction of Outcome in Severe Preeclampsia
this summary studied the predictive values of factor V Leiden mutation , doppler indices , placental pathology to unfavorable fetal and maternal outcomes
- Conditions
- Leiden Factor V Deficiency,Preeclampsia, Doppler Examination, Palental Pathology
- Trial name
- NCT03871764
- Testing
- blood sample , doppler of uterine vessel and placenta
- Volunteers
- 100 people
- Sponsor
- Cairo University
Thrombosis
Thrombophilic Risk Factors in Pediatric Patients Diagnosed at the Ha'Emek Medical Center
The study will assess the clinical and laboratory data of about 100 pediatric patients diagnosed and treated at the Pediatric Hematology Unit during the years 1980 until 2007 because of thrombotic events.
- Trial name
- NCT00736008
- Testing
- Observational
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- HaEmek Medical Center, Israel
Rare Bleeding Disorders
Rare Bleeding Disorders in the Netherlands
Rationale: Rare bleeding disorders (deficiency of fibrinogen, factor II, V, V\&VIII, VII, X, XI, XIII, α2-antiplasmin or plasminogen activator inhibitor 1) are not well defined with respect to their clinical phenotype, laboratory…
- Trial name
- RBIN (NCT03347591)
- Testing
- WES, Several assays
- Where
- 7 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- Radboud University Medical Center
Factor V Leiden, Factor II
Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test
To establish the overall agreement of the MassPLEX Factor II and Factor V Leiden Genotyping Test with bi-directional DNA sequencing for Factor II and Factor V Leiden.
- Conditions
- Factor V Leiden, Factor II, Thrombosis
- Trial name
- NCT01835483
- Where
- 3 sites in United States
- Volunteers
- 867 people
- Sponsor
- Sequenom, Inc.
Factor V Leiden, Prothrombin G20210A
A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism
This is a first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled, single ascending and multiple dose study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of…
- Conditions
- Factor V Leiden, Prothrombin G20210A, Venous Thromboembolism (VTE)
- Trial name
- NCT07430397
- Testing
- CITY-FXI
- Where
- United Kingdom
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- City Therapeutics
Liver Transplant Failure
Plasmatic Factor V as a Predictor of Graft Dysfunction After Liver Transplantation
Factor V is a coagulation cofactor that is primarily produced by the liver. Previous data has suggested a correlation between factor V levels and graft dysfunction.
- Trial name
- NCT03396016
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- University Health Network, Toronto
Detection and Genotyping of Factor V and Factor II Point Mutations
Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point Mutations in DNA
As an external validation test of the performance of the VeraCode Genotyping Test for Factor V and Factor II on the BeadXpress System, clinical trials will be conducted at three sites.
- Trial name
- NCT00959504
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- Illumina, Inc.
Infertility
Factor V Leiden Mutation and Implantation Failure
The purpose of this study is to determine whether inherited thrombophilias (tendency toward blood clotting) increase the risk of failure of the embryo to implant in IVF.
- Trial name
- NCT00194350
- Testing
- Test for Factor V Leiden gene mutation
- Where
- United States
- Volunteers
- 399 people
- Sponsor
- University of Pennsylvania
Factor V Leiden, Prothrombin G20210A
Engagement Study for Participants With Factor V Leiden and Prothrombin G20210A Mutations
This study will enrol individuals who have, or may have, Factor V Leiden or Prothrombin G20210A mutations, which are genetic changes linked to an increased risk of blood clots.
- Trial name
- NCT07584265
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Richmond Research Institute
Preeclampsia
LMWH to Prevent Preeclampsia and Fetal Growth Restriction
The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history…
- Trial name
- NCT00260520
- Testing
- Dalteparin
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Florence
Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation
Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor
Background : pregnancy and postpartum period are times of increased risk for deep vein thrombosis (DVT). The incidence of venous thromboembolic disease (VTE) during pregnancy is estimated at 1-2 per 1,000, and this risk increases…
- Conditions
- Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation, Pregnancy, Postpartum
- Trial name
- POSTPART AS5-2 (NCT07342127)
- Testing
- Retrospective collection of health data, Phone call to every participant
- Where
- 2 sites in France
- Volunteers
- 86 people
- Sponsor
- Hospices Civils de Lyon
Chronic Disease, Endocrine System Disease
Identify Genetic Variations That Affect The Ability of Patients To Metabolize Drugs Through Metabolic Pathways
This observation will look at patient care decisions of the primary healthcare provider utilizing the results of the DNA testing of patients' metabolic pathways using 2C19, 2C9, 2D6, 3A4, Factor II, Factor V and MTHFR and VKORC1.
- Conditions
- Chronic Disease, Endocrine System Disease, Cardiovascular Disease, Respiratory Tract Disease
- Trial name
- NCT02525887
- Testing
- Observation
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bracane Company
Abnormalities, Blood Coagulation Disorder
Study of Abnormal Blood Clotting in Children With Stroke
Effective treatment and prevention strategies for childhood stroke and porencephaly can only be developed once the causes are understood.
- Conditions
- Abnormalities, Blood Coagulation Disorder, Brain Disease, Cerebrovascular Accident
- Trial name
- NCT00001927
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Menopause, Thrombophilia
Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women
The purpose of this study is to determine if Femeralle (DT56a) has an effect on the coagulation system, measured by platelet adhesion and aggregation, of normal and thrombophilic postmenopausal women.
- Trial name
- NCT00883272
- Testing
- DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Patients Without a Medical History of Thrombosis or Hemorrhage, Hemophilic Patient
Evaluation of the Inter-center Variability of the Measurement of Thrombin Generation by the ST Genesia System
The thrombin generation test is a global test for the study of coagulation that allows the fine study of the balance between procoagulant and anticoagulant factors.
- Conditions
- Patients Without a Medical History of Thrombosis or Hemorrhage, Hemophilic Patient, Patient With FV Leiden Mutation, Patient With Cirrhosis
- Trial name
- EVIGE (NCT05422157)
- Where
- France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Clermont-Ferrand